Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]
Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]